Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4Melanoma 3Urinary Bladder Neoplasms 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1B-Cell Malignancies 1Advanced Solid Tumors 1Advanced Solid Malignancies 1

Interventions

pembrolizumab 91Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 25Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × urelumab × Clear all
NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
15 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡